A capsid virus-like particle-based SARS-CoV-2 vaccine induces high levels of antibodies and protects Rhesus macaques

Research output: Contribution to journal › Journal article › Research › peer-review

Standard

A capsid virus-like particle-based SARS-CoV-2 vaccine induces high levels of antibodies and protects Rhesus macaques. / Volkmann, Ariane; Koopman, Gerrit; Mooij, Petra; Verschoor, Ernst J; Verstrepen, Babs E; Bogers, Willy M J M; Idorn, Manja; Paludan, Søren R; Vang, Søren; Nielsen, Morten A; Sander, Adam F; Schmittwolf, Carolin; Hochrein, Hubertus; Chaplin, Paul.

In: Frontiers in Immunology, Vol. 13, 2022, p. 857440.

Research output: Contribution to journal › Journal article › Research › peer-review

Harvard

Volkmann, A, Koopman, G, Mooij, P, Verschoor, EJ, Verstrepen, BE, Bogers, WMJM, Idorn, M, Paludan, SR, Vang, S, Nielsen, MA, Sander, AF, Schmittwolf, C, Hochrein, H & Chaplin, P 2022, 'A capsid virus-like particle-based SARS-CoV-2 vaccine induces high levels of antibodies and protects Rhesus macaques', Frontiers in Immunology, vol. 13, pp. 857440. https://doi.org/10.3389/fimmu.2022.857440

APA

Volkmann, A., Koopman, G., Mooij, P., Verschoor, E. J., Verstrepen, B. E., Bogers, W. M. J. M., Idorn, M., Paludan, S. R., Vang, S., Nielsen, M. A., Sander, A. F., Schmittwolf, C., Hochrein, H., & Chaplin, P. (2022). A capsid virus-like particle-based SARS-CoV-2 vaccine induces high levels of antibodies and protects Rhesus macaques. Frontiers in Immunology, 13, 857440. https://doi.org/10.3389/fimmu.2022.857440

Vancouver

Volkmann A, Koopman G, Mooij P, Verschoor EJ, Verstrepen BE, Bogers WMJM et al. A capsid virus-like particle-based SARS-CoV-2 vaccine induces high levels of antibodies and protects Rhesus macaques. Frontiers in Immunology. 2022;13:857440. https://doi.org/10.3389/fimmu.2022.857440

Author

Volkmann, Ariane ; Koopman, Gerrit ; Mooij, Petra ; Verschoor, Ernst J ; Verstrepen, Babs E ; Bogers, Willy M J M ; Idorn, Manja ; Paludan, Søren R ; Vang, Søren ; Nielsen, Morten A ; Sander, Adam F ; Schmittwolf, Carolin ; Hochrein, Hubertus ; Chaplin, Paul. / A capsid virus-like particle-based SARS-CoV-2 vaccine induces high levels of antibodies and protects Rhesus macaques. In: Frontiers in Immunology. 2022 ; Vol. 13. pp. 857440.

Bibtex

@article{006c1dc09efc4aed88e6f89dbe966b67,
title = "A capsid virus-like particle-based SARS-CoV-2 vaccine induces high levels of antibodies and protects Rhesus macaques",
abstract = "Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused a worldwide pandemic. Here, we present non-human primate immunogenicity and protective efficacy data generated with the capsid virus-like particle (cVLP)-based vaccine ABNCoV2 that has previously demonstrated immunogenicity in mice. In rhesus macaques, a single vaccination with either 15 or 100 μg ABNCoV2 induced binding and neutralizing antibodies in a dose-dependent manner, at levels comparable to those measured in human convalescents. A second vaccine administration led to a >50-fold increase in neutralizing antibodies, with 2-log higher mean levels in the 100-μg ABNCoV2 group compared with convalescent samples. Upon SARS-CoV-2 challenge, a significant reduction in viral load was observed for both vaccine groups relative to the challenge control group, with no evidence of enhanced disease. Remarkably, neutralizing antibody titers against an original SARS-CoV-2 isolate and against variants of concern were comparable, indicating a potential for broad protection afforded by ABNCoV2, which is currently in clinical testing.",
keywords = "Animals, Antibodies, Neutralizing, Antibodies, Viral, COVID-19/prevention & control, COVID-19 Vaccines, Capsid, Capsid Proteins, Humans, Macaca mulatta, Mice, Mice, Inbred BALB C, SARS-CoV-2, Viral Vaccines",
author = "Ariane Volkmann and Gerrit Koopman and Petra Mooij and Verschoor, {Ernst J} and Verstrepen, {Babs E} and Bogers, {Willy M J M} and Manja Idorn and Paludan, {S{\o}ren R} and S{\o}ren Vang and Nielsen, {Morten A} and Sander, {Adam F} and Carolin Schmittwolf and Hubertus Hochrein and Paul Chaplin",
note = "Copyright {\textcopyright} 2022 Volkmann, Koopman, Mooij, Verschoor, Verstrepen, Bogers, Idorn, Paludan, Vang, Nielsen, Sander, Schmittwolf, Hochrein and Chaplin.",
year = "2022",
doi = "10.3389/fimmu.2022.857440",
language = "English",
volume = "13",
pages = "857440",
journal = "Frontiers in Immunology",
issn = "1664-3224",
publisher = "Frontiers Research Foundation",

}

RIS

TY - JOUR

T1 - A capsid virus-like particle-based SARS-CoV-2 vaccine induces high levels of antibodies and protects Rhesus macaques

AU - Volkmann, Ariane

AU - Koopman, Gerrit

AU - Mooij, Petra

AU - Verschoor, Ernst J

AU - Verstrepen, Babs E

AU - Bogers, Willy M J M

AU - Idorn, Manja

AU - Paludan, Søren R

AU - Vang, Søren

AU - Nielsen, Morten A

AU - Sander, Adam F

AU - Schmittwolf, Carolin

AU - Hochrein, Hubertus

AU - Chaplin, Paul

N1 - Copyright © 2022 Volkmann, Koopman, Mooij, Verschoor, Verstrepen, Bogers, Idorn, Paludan, Vang, Nielsen, Sander, Schmittwolf, Hochrein and Chaplin.

PY - 2022

Y1 - 2022

N2 - Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused a worldwide pandemic. Here, we present non-human primate immunogenicity and protective efficacy data generated with the capsid virus-like particle (cVLP)-based vaccine ABNCoV2 that has previously demonstrated immunogenicity in mice. In rhesus macaques, a single vaccination with either 15 or 100 μg ABNCoV2 induced binding and neutralizing antibodies in a dose-dependent manner, at levels comparable to those measured in human convalescents. A second vaccine administration led to a >50-fold increase in neutralizing antibodies, with 2-log higher mean levels in the 100-μg ABNCoV2 group compared with convalescent samples. Upon SARS-CoV-2 challenge, a significant reduction in viral load was observed for both vaccine groups relative to the challenge control group, with no evidence of enhanced disease. Remarkably, neutralizing antibody titers against an original SARS-CoV-2 isolate and against variants of concern were comparable, indicating a potential for broad protection afforded by ABNCoV2, which is currently in clinical testing.

AB - Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused a worldwide pandemic. Here, we present non-human primate immunogenicity and protective efficacy data generated with the capsid virus-like particle (cVLP)-based vaccine ABNCoV2 that has previously demonstrated immunogenicity in mice. In rhesus macaques, a single vaccination with either 15 or 100 μg ABNCoV2 induced binding and neutralizing antibodies in a dose-dependent manner, at levels comparable to those measured in human convalescents. A second vaccine administration led to a >50-fold increase in neutralizing antibodies, with 2-log higher mean levels in the 100-μg ABNCoV2 group compared with convalescent samples. Upon SARS-CoV-2 challenge, a significant reduction in viral load was observed for both vaccine groups relative to the challenge control group, with no evidence of enhanced disease. Remarkably, neutralizing antibody titers against an original SARS-CoV-2 isolate and against variants of concern were comparable, indicating a potential for broad protection afforded by ABNCoV2, which is currently in clinical testing.

KW - Animals

KW - Antibodies, Neutralizing

KW - Antibodies, Viral

KW - COVID-19/prevention & control

KW - COVID-19 Vaccines

KW - Capsid

KW - Capsid Proteins

KW - Humans

KW - Macaca mulatta

KW - Mice

KW - Mice, Inbred BALB C

KW - SARS-CoV-2

KW - Viral Vaccines

U2 - 10.3389/fimmu.2022.857440

DO - 10.3389/fimmu.2022.857440

M3 - Journal article

C2 - 35479095

VL - 13

SP - 857440

JO - Frontiers in Immunology

JF - Frontiers in Immunology

SN - 1664-3224

ER -

ID: 304747842